"Rivastigmine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE.
| Descriptor ID |
D000068836
|
| MeSH Number(s) |
D02.241.081.251.583.899
|
| Concept/Terms |
Rivastigmine- Rivastigmine
- (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate
RivastigmineTartrate- RivastigmineTartrate
- Rivastigmine Hydrogen Tartrate
- Hydrogen Tartrate, Rivastigmine
- Tartrate, Rivastigmine Hydrogen
ENA 713- ENA 713
- 713, ENA
- SDZ ENA 713
- 713, SDZ ENA
- ENA 713, SDZ
- ENA-713
- ENA713
|
Below are MeSH descriptors whose meaning is more general than "Rivastigmine".
Below are MeSH descriptors whose meaning is more specific than "Rivastigmine".
This graph shows the total number of publications written about "Rivastigmine" by people in this website by year, and whether "Rivastigmine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rivastigmine" by people in Profiles.
-
Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study. Drugs Aging. 2022 06; 39(6):453-465.
-
Risk of overactive bladder associated with cholinesterase inhibitors in dementia. J Am Geriatr Soc. 2022 03; 70(3):820-830.
-
Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical Trial. J Neurotrauma. 2021 07 15; 38(14):1943-1952.
-
Rivastigmine does not alter cocaine-induced subjective effects or self-administration. Pharmacol Biochem Behav. 2019 10; 185:172758.
-
Preliminary findings of the effects of rivastigmine, an acetylcholinesterase inhibitor, on working memory in cocaine-dependent volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Apr 03; 50:137-42.
-
Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27; 37(1):141-6.
-
Cholinesterase inhibitor initiation in hospital setting. J Am Geriatr Soc. 2011 Oct; 59(10):1988-9.
-
Evaluation of the effects of rivastigmine on cigarette smoking by methamphetamine-dependent volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 01; 35(8):1827-30.
-
Low dose, short-term rivastigmine administration does not affect neurocognition in methamphetamine dependent individuals. Pharmacol Biochem Behav. 2011 Sep; 99(3):423-7.
-
Long-term effects of rivastigmine capsules in patients with traumatic brain injury. Brain Inj. 2009 Feb; 23(2):123-32.